Table 1.

Predictor use in development studies (N =19)

	Age	Sex	World religion	Race	Smoking	BMI	Type of AF	Previous stroke/TIAa	Previous bleeding	Vascular disease	Heart failure	Hypertension	Diabetes mellitus	Chronic kidney disease	Dementia	Antiplatelet	Oral anticoagulant	Other treatmentb	Time in therapeutic range	IMRSa	cTnI/T-hsa	NT-proBNPa	Proteinuria	Creatinine clearance	PT-INRa	Blood pressure	Left atrial dimension
	Patient characteristics							Comorbidities								Treatment				Laboratory findings						Clinical findings
AFI investigators, 1994	x							x				x	x
Hart, 1999	x	x										x														x
Gage, 2001	x							x			x	x	x
Van Walraven, 2003								x		x			x													x
Wang, 2003	x	x						x					x													x
Rietbrock, 2008	x	x						x					x
Lip, 2010	x2	x						x		x	x	x	x
Lip, 2013	x							x								x			x
Singer, 2013	x	x									x	x	x										x	x
Hijazi, 2016	x							x													x	x
Fox, 2017			x	x				x	x		x			x			x
Claxton, 2019	x	x						x	x							x	x3	x5
Horne, 2019	x	x						x				x	x				x			x7
Shin, 2019	x																					x		x			x
Goto, 2019																									x
Jiang 2020	x							x			x
Fox, 2021	x				x			x	x	x	x	x	x	x	x		x
Okumara, 2021	x2					x	x	x				x
Arnson, 2021	x									x		x	x	x2

The inclusion of a predictor is shown as ‘x’. The subscript under x indicates the number of predictors included from that category (e.g. ‘x2’ implies that 2 predictors were used from the same category).

^acTnI/T-hs, high-sensitive cardiac troponin I/T; IMRS, intermountain risk score (consists of complete blood count parameters and basic metabolic factors); NT-proBNP, N-terminal-pro hormone Brain natriuretic peptide; PT-INR, prothrombin time international normalized ratio; TIA, transient ischemic attack.

^bAntiarrhythmic, calcium channer blocker, beta Blocker, lipid lowering medication, or anti-diabetic medication.